Relationship between the use of hormonal contraceptives and the development of breast cancer: controversies in the literature
Article Sidebar
Main Article Content
Abstract
Objective: To analyze the controversies of the relationship between the use of oral hormonal contraceptives and breast cancer. Bibliographic review: The oral hormonal contraceptive is an effective contraceptive method, it has low cost and is available in the unified health system. However, the controlled flow of false news on social networks constantly associates hormonal contraceptives with an increase in the incidence of breast cancer (CA), giving rise to an irrational fear in the population. The scientific literature demonstrates how controversial this subject is: some studies describe a positive relationship; others describe that there are none. The articles agree that other risk factors such as age, genetic predisposition, obesity and lifestyle have greater resistance in the development of breast cancer than the contraceptive itself. In this way, the health professional must adapt a unique plan, instruct his patient with real scientific information about contraceptive methods and choose together according to their individualities. Final considerations: There are many controversies involving the risks of using contraceptive hormones in the development of breast cancer, not being unanimous among the analised studies.
Article Details
Copyright © | All rights reserved.
The journal holds the exclusive copyright for the publication of this article under the terms of Brazilian law 9610/98.
Partial reproduction
The use of parts of the texts, figures and questionnaire of the article is free, being mandatory the citation of the authors and journal.
Total reproduction
It is expressly prohibited and must be authorized by the journal.
References
2. BONFIGLIO R e DI PIETRO ML. The impact of oral contraceptive use on breast cancer risk: State of the art and future perspectives in the era of 4P medicine. Seminars in Cancer Biology, 2021; 72: 11–18.
3. BYRNE C, et al. Mammographic Density Change With Estrogen and Progestin Therapy and Breast Cancer Risk. Journal of the National Cancer Institute, 2017; 109(9).
4. BREAST. 2020. In: Global Cancer Observatory. Disponível em: https://gco.iarc.fr/today/data/factsheets/cancers/20-Breast-fact-sheet.pdf. Acessado em: 8 de fevereiro de 2023.
5. CARDOSO MPC. Associação entre câncer de mama e uso de contraceptivos orais de mulheres em idade fértil. Tese (Doutorado em Ciências Médico-Cirúrgicas) - Faculdade de Medicina, Universidade Federal do Ceará, Fortaleza, 2020, 58 p.
6. COSTA LS, et al. Fatores de risco relacionados ao câncer de mama e a importância da detecção precoce para a saúde da mulher. Revista Eletrônica Acervo Científico, 2021; 31: e8174.
7. COUTO PLS, et al. Evidências dos efeitos adversos no uso de anticoncepcionais hormonais orais em mulheres: uma revisão integrativa. Enfermagem em Foco, 2020. 11(4).
8. DORCHAK JA, et al. The Impact of Hormonal Contraceptives on Breast Cancer Pathology. Hormones & Cancer, 2018; 9(4): 240–253.
9. HUBER D, et al. Use of oral contraceptives in BRCA mutation carriers and risk for ovarian and breast cancer: a systematic review. Archives of Gynecology and Obstetrics, 2020; 301: 875–884.
10. JUREMA KKC e JUREMA, HC. Efeitos Colaterais a longo prazo associados ao uso de Anticoncepcionais Hormonais Orais. Revista Cereus, 2021; 13: 124-135.
11. KAMANI M, et al. Review of the literature on combined oral contraceptives and cancer. ecancermedicalscience, 2022; 16: 1416.
12. ŁUKASIEWICZ S, et al. Breast cancer—epidemiology, risk factors, classification, prognostic markers, and current treatment strategies—an updated review. Cancers, 2021; 13: 4287.
13. MARSDEN J. Hormonal contraception and breast cancer, what more do we need to know? Post Reproductive Health, 2017; 23(3): 116–127.
14. MØRCH LS, et al. Contemporary Hormonal Contraception and the Risk of Breast Cancer. New England Journal of Medicine, 2017; 377: 2228–2239.
15. OLIVEIRA ALR, et al. Fatores de risco e prevenção do câncer de mama. Cadernos da Medicina-UNIFESO, 2020; 2: 135-145.
16. PARK J, et al. Oral contraceptives and risk of breast cancer and ovarian cancer in women with a BRCA1 or BRCA2 mutation: a meta-analysis of observational studies. Carcinogenesis, 2022; 43:231–242.
17. PEREIRA BMB, et al. Terapia hormonal e câncer de mama. Rev Bras Mastologia, 2017; 27: 15-20.
18. ROMANO F, et al. Estudo epidemiológico e intervencionista sobre uso de anticoncepcionais como método contraceptivo. Revista da Faculdade de Ciências Médicas de Sorocaba, 2020; 22: 4(146–50).
19. SCHRIJVER L, et al. Oral Contraceptive Use and Breast Cancer Risk: Retrospective and Prospective Analyses From a BRCA1 and BRCA2 Mutation Carrier Cohort Study. JNCI Cancer Spectrum, 2018; 2: pky023.
20. VAN HOFTEN C, et al. Long-term oral contraceptive use increases breast cancer risk in women over 55 years of age: the DOM cohort. International Journal of Cancer, 2000; 87(4): 591–594.
21. WESTHOFF CL, PIKE MC. Hormonal contraception and breast cancer. Contraception, 2018; 98: 171–173.
22. ZOLFAROLI I, et al. The action of estrogens and progestogens in the young female breast. European Journal of Obstetrics & Gynecology and Reproductive Biology, 2018; 230: 204–207.